Targeted drug for recurrent brain cancer with STAT3 marker
Part of Cancer clinical trials.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer) and your tumor must have a specific marker called STAT3-high.
- You must have already had radiation therapy and your tumor must have come back (recurred) after treatment.
- You must be at least 21 years old.
- You should be generally active and able to care for yourself (Karnofsky performance status of 70 or higher).
- Your blood counts, kidney, and liver function need to be within acceptable ranges.
- You cannot have cancer that has spread to other parts of the body or to the lining of the brain and spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a new drug called CT-179 for people with glioblastoma, an aggressive type of brain cancer. The drug targets a protein that helps cancer cells grow, and the goal is to see if it is safe and whether it can slow the tumor down.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
This trial tests a new treatment for recurrent glioblastoma, a type of brain cancer that has returned. The treatment uses your own immune cells, modified in a lab to find and attack a specific marker on the tumor, called EGFRvIII. It might help because it targets the cancer cells directly and may slow or stop their growth.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.